home > ebr

European Biopharmaceutical Review


European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:


David Hirsh

Giovanni Farina 


Emma Naks

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.

View the
digital version
of EBR

Featured in this issue
Legal, Regulatory and Public Policy
Personalised Medicine

Individual Focus

With molecular profi ling allowing for patient-specific therapeutic strategies, the need to encourage research must be balanced against demands for privacy protection, reports Emma Naks at EBR.
BioDevelopment and Regulatory
Temperature Standardisation

Playing it Cool

Rolf Ehrhardt and Maria Thompson from BioCision raise awareness of the importance of temperature standardisation in the field of cell biology, and evaluate current practice.
  Science and Innovation
Column Technology

HPLC’s Golden Jubilee: Part 2

In the second of a two-part series, Ronald Majors from Agilent Technologies reviews the progress of highperformance liquid chromatography over the last 50 years and considers what the future holds.

Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

Banner of Ionicon.EBR on Samedan
Banner of Agilent.EBR on Samedan
Industry Events

Annual World Drug Manufacturing Summit

1-3 December 2014, Berlin, Germany

Now in its 13th year, the World Drug Manufacturing Summit provides the key tools to overcome the biggest threats facing pharma manufacturers today.
More info >>

News and Press Releases

ICON Honours Irish-American Healthcare Innovators

Dublin, Ireland, 22 September, 2014 – ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it is co-hosting the inaugural Irish America Healthcare and Life Sciences 50 awards. The event, to be held in partnership with Irish America magazine, takes place at the New York Yacht Club on September 25th and recognises the excellent contributions of Irish-Americans in the fields of pharmaceuticals, biotechnology, medical devices, research and development and life sciences venture capital.
More info >>

air transport logo


White Papers

Interface: Drug Delivery Devices


A family is packing for its annual summer trek to the cottage by the lake. Along with fishing gear, sunscreen, and life vests, the checklist also includes another kind of life saver – an autoinjector that delivers two doses of epinephrine to treat anaphylaxis, a severe and potentially lifethreatening allergic reaction.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement